Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ON 01910.Na in Platinum-resistant Ovarian Cancer
NCT00856791Phase 2Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- Mar 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rigosertib in ovarian cancer, sponsored by Traws Pharma, Inc. Primary endpoint: Progression Free Survival at 6 months. Started Mar 2009; status: completed.
02
Drugs
rigosertib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00856791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856791.